{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:07:48Z","timestamp":1783908468042,"version":"3.55.0"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                    : Cytomegalovirus (CMV) is the most common opportunistic infective pathogen in kidney transplant recipients. Valganciclovir (VAL) is commonly used for prophylaxis, especially in high-risk recipients. Generic VAL formulations have become available, but the data about their safety and efficacy are lacking.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : Consecutive de novo kidney transplant patients were randomized to generic VAL Valganciklovir Teva\u00ae (VT group)(24 patients) or Alvanocyte\u00ae (A group), Alvogen (19 patients) or to Valcyte\u00ae (V group), Roche (23 patients) in a 18-month open-label study. Universal prophylaxis was used for 6 months after the transplantation. CMV DNA levels were measured at 1,3,6,9,12 and 18 months after the transplantation. All positive measurements of CMV DNA were recorded.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Groups did not differ regarding the clinical characteristics or the risk for developing CMV infection in the post-transplant period. CMV replications were most common at 9 months after the transplantation with rates of 9% for the V, 13% for the VT and 26% for the A group (p=0.26). At 12 months, positive CMV DNA was recorded in 22%, 8% and 11 % of patients taking V, VT and A, respectively (p=0.37). Rates of biopsy-proven acute rejection, adverse events, and serious adverse events were similar for all formulations. Lymphocele occurred most commonly in the V group (35%) compared to 17% in VT and 17% in the A group (p=0.23). One patient from each of the A and VT groups developed CMV disease. Additionally, they were the only two patients with CMV DNA copies above 656 IU\/ml. Glomerular filtration rates were similar in all groups at all time points, while proteinuria was significantly higher at 12 months in patients who received V 0.32 g\/day (0.18 \u2013 0.42), compared to patients on VT 0.2 (0.1 \u2013 0.2), or A 0.2 (0.2 \u2013 0.3), p=0.04.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : Valgancyclovir efficacy and safety in this limited data set is similar with early administration of V, VT and A after kidney transplantation. Additional studies aimed at elucidating the effectiveness of this treatment regimen in patients who are at high risk for developing CMV infection are necessary to draw further conclusions.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2020-0004","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T04:31:10Z","timestamp":1582864270000},"page":"47-55","source":"Crossref","is-referenced-by-count":1,"title":["A Comparison of Different Valgancyclovir Formulations in the Universal 6-Month Prophylaxis Against CMV Infection in Renal Transplant Recipients: A Randomized Single-Centre Study"],"prefix":"10.2478","volume":"40","author":[{"given":"Nikolina","family":"Basic-Jukic","sequence":"first","affiliation":[{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation , University Hospital Centre Zagreb , Croatia"},{"name":"Faculty of Medicine , University of Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Furic-Cunko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation , University Hospital Centre Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tvrtko","family":"Hudolin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Zagreb , Croatia"},{"name":"Department of Urology , University Hospital Centre Zagreb , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Zimak","sequence":"additional","affiliation":[{"name":"Department of Urology , University Hospital Centre Zagreb , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kirincich","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Kastelan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Zagreb , Croatia"},{"name":"Department of Urology , University Hospital Centre Zagreb , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"2026071214393891697_j_prilozi-2020-0004_ref_001_w2aab3b8b8b1b7b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician\u2019s update. Am J Kidney Dis. 2011; 58(1): 118\u2013126.10.1053\/j.ajkd.2011.04.010","DOI":"10.1053\/j.ajkd.2011.04.010"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_002_w2aab3b8b8b1b7b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Freeman RB., Jr. The \u2018indirect\u2019 effects of cytomegalovirus infection. Am J Transplant. 2009; 9: 2453\u20132458.10.1111\/j.1600-6143.2009.02824.x","DOI":"10.1111\/j.1600-6143.2009.02824.x"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_003_w2aab3b8b8b1b7b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013: CD003774.10.1002\/14651858.CD003774.pub4","DOI":"10.1002\/14651858.CD003774.pub4"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_004_w2aab3b8b8b1b7b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010; 10: 1228\u20131237.10.1111\/j.1600-6143.2010.03074.x","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_005_w2aab3b8b8b1b7b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003; 3 Suppl 4: 114\u2013125.10.1034\/j.1600-6143.3.s4.11.x","DOI":"10.1034\/j.1600-6143.3.s4.11.x"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_006_w2aab3b8b8b1b7b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Selvey LA, Lim WH, Boan P, et al. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. BMC Infect Dis 2017; 17(1): 501.10.1186\/s12879-017-2599-y","DOI":"10.1186\/s12879-017-2599-y"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_007_w2aab3b8b8b1b7b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 2014 Mar; 58(6): 785\u2013803.10.1093\/cid\/cit945","DOI":"10.1093\/cid\/cit945"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_008_w2aab3b8b8b1b7b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013; 85(5): 893\u2013898.10.1002\/jmv.23539","DOI":"10.1002\/jmv.23539"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_009_w2aab3b8b8b1b7b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013; 26: 703\u2013727.10.1128\/CMR.00015-13","DOI":"10.1128\/CMR.00015-13"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_010_w2aab3b8b8b1b7b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Martin-Gandul C, Perez-Romero P, Sanchez M, et al. Spanish network for research in infectious D: determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol. 2013; 56: 13\u201318.10.1016\/j.jcv.2012.09.017","DOI":"10.1016\/j.jcv.2012.09.017"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_011_w2aab3b8b8b1b7b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013; 13: 93\u2013106.10.1111\/ajt.12103","DOI":"10.1111\/ajt.12103"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_012_w2aab3b8b8b1b7b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. Torre-Cisneros J, Aguado JM, Caston JJ et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations. Transplant Rev (Orlando) 2016; 30: 119\u2013143.10.1016\/j.trre.2016.04.001","DOI":"10.1016\/j.trre.2016.04.001"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_013_w2aab3b8b8b1b7b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Halimi JM. Low-grade proteinuria and microalbuminuria in renal transplantation. Transplantation. 2013; 96(2): 121\u2013130.10.1097\/TP.0b013e31828719fb","DOI":"10.1097\/TP.0b013e31828719fb"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_014_w2aab3b8b8b1b7b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int. 2012; 25(9): 909\u2013917.10.1111\/j.1432-2277.2012.01500.x","DOI":"10.1111\/j.1432-2277.2012.01500.x"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_015_w2aab3b8b8b1b7b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Liang X, Famure O, Li Y, Kim SJ. Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis. Prog Transplant. 2018; 28(2): 124\u2013133.10.1177\/1526924818765798","DOI":"10.1177\/1526924818765798"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_016_w2aab3b8b8b1b7b1ab1ac16Aa","unstructured":"16. Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation. 2019 Feb 19.10.1097\/TP.0000000000002626"},{"key":"2026071214393891697_j_prilozi-2020-0004_ref_017_w2aab3b8b8b1b7b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. Vilibic-Cavlek T, Kolaric B, Bogdanic M, Tabain I, Beader N. Herpes Group Viruses: a Seroprevalence Study in Hemodialysis Patients. Acta Clin Croat. 2017; 56(2): 255\u2013261.10.20471\/acc.2017.56.02.08","DOI":"10.20471\/acc.2017.56.02.08"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/prilozi\/40\/3\/article-p47.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2020-0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:32:21Z","timestamp":1783906341000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2020-0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,27]]},"published-print":{"date-parts":[[2019,12,1]]}},"alternative-id":["10.2478\/prilozi-2020-0004"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2020-0004","relation":{},"ISSN":["1857-8985","1857-9345"],"issn-type":[{"value":"1857-8985","type":"electronic"},{"value":"1857-9345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}